Erratum: Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial (The Lancet (2018) 391(10125) (1085–1096)(S0140673618301363)(10.1016/S0140-6736(18)30136-3));Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet

Volumn 391, Issue 10125, 2018, Pages 1085-1096

  Thiele, Elizabeth A ^a   Marsh, Eric D ^b   French, Jacqueline A ^c   Mazurkiewicz, Maria B ^d,k   Benbadis, Selim R ^e   Joshi, Charuta ^f,k   Lyons, Paul D ^g   Taylor, Adam ^h   Roberts, Claire ^h   Sommerville, Kenneth ^i,j   Gunning, Boudewjin ^k   Gawlowicz, Jacek ^k   Lisewski, Pawel ^k   Mitosek Szewczyk, Krystyna ^k   Steinborn, Barbara ^k   Zolnowska, Marta ^k   Hughes, Elaine ^k   McLellan, Ailsa ^k   Benbadis, Selim ^k   Ciliberto, Michael ^k   Clark, Gary ^k   Dlugos, Dennis ^k   Filloux, Francis ^k   Flamini, Robert ^k   French, Jacqueline ^k   Frost, Michael ^k   Haut, Sheryl ^k   Kapoor, Siddarth ^k   Kessler, Sudha ^k   Laux, Linda ^k   Lyons, Paul ^k   Marsh, Eric ^k   Moore, David ^k   Morse, Richard ^k   Nagaraddi, Venkatesh ^k   Rosenfeld, William ^k   Seltzer, Laurie ^k   Shellhaas, Renée ^k   Thiele, Elizabeth ^k   Thio, Liu Lin ^k   Wang, David ^k   Wilfong, Angus ^k   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f CHILDREN S HOSPITAL COLORADO   (United States)

^g Winchester Neurological Consultants   (United States)

^h Porton Down Science Park   (United Kingdom)

ⁱ GW Pharmaceuticals Ltd   (United States)

^j DUKE UNIVERSITY   (United States)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CLOBAZAM; LAMOTRIGINE; LEVETIRACETAM; PLACEBO; RUFINAMIDE; VALPROIC ACID; ANTICONVULSIVE AGENT;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; CAREGIVER; CHILD; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; FEVER; HUMAN; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PATIENT; PATIENT DROPOUT; PHASE 3 CLINICAL TRIAL; POLAND; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPIKE WAVE; TONIC CLONIC SEIZURE; UNITED STATES; VAGUS NERVE STIMULATION; VOMITING; YOUNG ADULT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTICONVULSANTS; CANNABIDIOL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LENNOX GASTAUT SYNDROME; MALE; MIDDLE AGED; SEIZURES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85041583750     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30566-X     Document Type: Erratum

References (28)

1. van Rijckevorsel, K, Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat 4 (2008), 1001–1019.
2. Autry, AR, Trevathan, E, Van Naarden Braun, K, Yeargin-Allsopp, M, Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol 25 (2010), 441–447.
3. Arzimanoglou, A, French, J, Blume, WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 8 (2009), 82–93.
4. Dura-Trave, T, Yoldi-Petri, ME, Gallinas-Victoriano, F, Epilepsy in children in Navarre, Spain: epileptic seizure types and epileptic syndromes. J Child Neurol 22 (2007), 823–828.
5. Trevathan, E, Murphy, CC, Yeargin-Allsopp, M, Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia 38 (1997), 1283–1288.
6. Doring, JH, Lampert, A, Hoffmann, GF, Ries, M, Thirty years of orphan drug legislation and the development of drugs to treat rare seizure conditions: a cross sectional analysis. PLoS One, 11, 2016, e0161660.
7. Montouris, GD, Wheless, JWTA, The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. Epilepsia 55:suppl 4 (2014), 10–20.
8. Hancock, EC, Cross, JH, Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev, 2013 CD003277.
9. Ng, YT, Conry, JA, Drummond, R, Stolle, J, Weinberg, MA, OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 77 (2011), 1473–1481.
10. Kang, HC, Kim, YJ, Kim, DW, Kim, HD, Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia 46 (2005), 272–279.
11. Cersosimo, RO, Bartuluchi, M, Fortini, S, Soraru, A, Pomata, H, Caraballo, RH, Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies. Epileptic Disord 13 (2011), 382–388.
12. Lancman, G, Virk, M, Shao, H, et al. Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis. Seizure 22 (2013), 3–8.
13. Douglass, LM, Salpekar, J, Surgical options for patients with Lennox-Gastaut syndrome. Epilepsia 55:suppl 4 (2014), 21–28.
14. Kossoff, EH, Shields, WD, Nonpharmacologic care for patients with Lennox-Gastaut syndrome: ketogenic diets and vagus nerve stimulation. Epilepsia 55:suppl 4 (2014), 29–33.
15. Bourgeois, BF, Douglass, LM, Sankar, R, Lennox-Gastaut syndrome: a consensus approach to differential diagnosis. Epilepsia 55:suppl 4 (2014), 4–9.
16. Ibeas Bih, C, Chen, T, Nunn, AV, Bazelot, M, Dallas, M, Whalley, BJ, Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12 (2015), 699–730.
17. Turner, SE, Williams, CM, Iversen, L, Whalley, BJ, Molecular pharmacology of phytocannabinoids. Kinghorn, AD, Falk, H, Gibbons, S, Kobayashi, J, (eds.) Phytocannabinoids: unraveling the complex chemistry and pharmacology of cannabis sativa, 2017, Springer International Publishing, Basel, Switzerland, 61–101.
18. Jones, NA, Hill, AJ, Smith, I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 332 (2010), 569–577.
19. Devinsky, O, Marsh, E, Friedman, D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15 (2016), 270–278.
20. Devinsky, O, Cross, JH, Laux, L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med 376 (2017), 2011–2020.
21. Kothare, S, Kluger, G, Sachdeo, R, et al. Dosing considerations for rufinamide in patients with Lennox-Gastaut sundrome: phase III trial results and real-world clinical data. Seizure 47 (2017), 25–33.
22. Devinsky O, Patel AD, Thiele EA, et al. A randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology (in press).
23. Purcarin, G, Ng, YT, Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome. Ther Adv Neurol Disord 7 (2014), 169–176.
24. US Department of Health and Human Services. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. https://www.fda.gov/downloads/Guidances/UCM174090.pdf, 2009 (accessed Dec 12, 2017).
25. Babalonis, S, Haney, M, Malcolm, RJ, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172 (2017), 9–13.
26. Glauser, T, Kluger, G, Sachdeo, R, Krauss, G, Perdomo, C, Arroyo, S, Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 70 (2008), 1950–1958.
27. Lundbeck. ONFI® (clobazam): full prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2016/203993s005lbl.pdf, 2016 (accessed Dec 12, 2017).
28. Geffrey, AL, Pollack, SF, Bruno, PL, Thiele, EA, Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56 (2015), 1246–1251.